SCHEMBL6204963

SCHEMBL6204963

CC(Nc1nccc(-c2c(-c3ccc(F)cc3)c(=O)n3n2Cc2ccccc2C3)n1)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.80
MAPK13 O15264 16/20 0.80
MAPK12 P53778 15/20 0.80
MAPK11 Q15759 15/20 0.80
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
LCK P06239 1/20 0.55
LYN P07948 1/20 0.55
MAPK1 P28482 1/20 0.55
AKT2 P31751 1/20 0.55
FLT4 P35916 1/20 0.55
FLT3 P36888 1/20 0.55
FRK P42685 1/20 0.55
MAPK8 P45983 1/20 0.55
MAPK9 P45984 1/20 0.55
CSNK1A1 P48729 1/20 0.55
CSNK1D P48730 1/20 0.55
GSK3A P49840 1/20 0.55
GSK3B P49841 1/20 0.55
CSNK1G2 P78368 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204962 1.00 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL4849225 0.89 MAPK13 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4849231 0.89 MAPK13 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6205650 0.89 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL4857955 0.89 MAPK13 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6203057 0.89 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6203194 0.87 MAPK14 (0.77) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6203884 0.85 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL6203885 0.85 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11PRKD3
SCHEMBL4857256 0.85 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1427727-B1 COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES PROCTER & GAMBLE (US) 2005-01-26 EP disclosed
US-6821971-B2 FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA THE PROCTER & GAMBLE COMPANY 2004-11-23 US disclosed
US-20030105084-A1 Compound which inhibit the release of inflammatory cytokines THE PROCTER & GAMBLE COMPANY 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105084-A1 Compound which inhibit the release of inflammatory cytokines IL1B, IL1A, TNF MAPK14 2211/4885MAPK13 2109/4885MAPK12 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.